Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes

The glycemic benefit of AID was observed across a wide range of participant characteristics. Furthermore, there were no identifiable characteristics that were associated with unsuccessful use of AID or a lack of beneficial glycemic response with AID. Therefore, AID should be a consideration for all adults with insulin-treated type 2 diabetes.